Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms.
Priesner C, Esser R, Tischer S, Marburger M, Aleksandrova K, Maecker-Kolhoff B, Heuft HG, Goudeva L, Blasczyk R, Arseniev L, Köhl U, Eiz-Vesper B, Klöß S. Priesner C, et al. Among authors: tischer s. Front Immunol. 2016 Sep 30;7:393. doi: 10.3389/fimmu.2016.00393. eCollection 2016. Front Immunol. 2016. PMID: 27746781 Free PMC article.
Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease.
Schultze-Florey RE, Tischer S, Kuhlmann L, Hundsdoerfer P, Koch A, Anagnostopoulos I, Ravens S, Goudeva L, Schultze-Florey C, Koenecke C, Blasczyk R, Koehl U, Heuft HG, Prinz I, Eiz-Vesper B, Maecker-Kolhoff B. Schultze-Florey RE, et al. Among authors: tischer s. Front Immunol. 2018 Jun 27;9:1475. doi: 10.3389/fimmu.2018.01475. eCollection 2018. Front Immunol. 2018. PMID: 29997626 Free PMC article.
Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes.
Tischer S, Kaireit T, Figueiredo C, Hiller O, Maecker-Kolhoff B, Geyeregger R, Immenschuh S, Blasczyk R, Eiz-Vesper B. Tischer S, et al. Int Immunol. 2012 Sep;24(9):561-72. doi: 10.1093/intimm/dxs059. Epub 2012 Jun 27. Int Immunol. 2012. PMID: 22740564
CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, Verboom M, Immenschuh S, Heim A, Borchers S, Mischak-Weissinger E, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Sukdolak C, et al. Among authors: tischer s. Biol Blood Marrow Transplant. 2013 Oct;19(10):1480-92. doi: 10.1016/j.bbmt.2013.07.015. Epub 2013 Jul 23. Biol Blood Marrow Transplant. 2013. PMID: 23891747 Free article.
Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor.
Bunse CE, Borchers S, Varanasi PR, Tischer S, Figueiredo C, Immenschuh S, Kalinke U, Köhl U, Goudeva L, Maecker-Kolhoff B, Ganser A, Blasczyk R, Weissinger EM, Eiz-Vesper B. Bunse CE, et al. Among authors: tischer s. PLoS One. 2013 Dec 4;8(12):e77925. doi: 10.1371/journal.pone.0077925. eCollection 2013. PLoS One. 2013. PMID: 24324576 Free PMC article.
Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B. Tischer S, et al. J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28. J Immunol Methods. 2014. PMID: 24877879
73 results